Canaccord Genuity Reiterates Buy on Allogene Therapeutics, Maintains $35 Price Target
Portfolio Pulse from richadhand@benzinga.com
Canaccord Genuity analyst John Newman has reiterated a Buy rating on Allogene Therapeutics (NASDAQ:ALLO) and maintained a $35 price target.
June 16, 2023 | 2:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Canaccord Genuity analyst John Newman reiterated a Buy rating on Allogene Therapeutics and maintained a $35 price target.
The Buy rating and maintained price target by Canaccord Genuity analyst John Newman indicates a positive outlook for Allogene Therapeutics. This news is likely to have a positive impact on the stock price in the short term as it reaffirms the analyst's confidence in the company's potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100